Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Stoke Therapeutics Logo
Stoke Therapeutics Growth Score
50
CB Rank
21645
Heat Score
47
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Founded
obfuscation
PublicPost-IPO Equity Bedford, Massachusetts, United States101-250 www.stoketherapeutics.com/
Biotechnology
Health Care
Pharmaceutical
Therapeutics
Overview

Stoke Therapeutics
Total Funding
obfuscation
Growth Score
50
Heat Score
47

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score50
-26 pts
in past quarter
Heat Score 47
-11 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Stoke Therapeutics

CB Rank
21645
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Founded
obfuscation
PublicPost-IPO Equity Bedford, Massachusetts, United States101-250 www.stoketherapeutics.com/
Biotechnology
Health Care
Pharmaceutical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Series B
OBF
in
obfuscation

Key People

Details

Legal Name Stoke Therapeutics
Operating Status Active
Stock Symbol  NASDAQ:STOK
Company Type For Profit
Founders  Adrian Krainer, Edward Kaye, Huw Nash, Isabel Aznarez
About the Company
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
Phone Number 781-430-8200
Contact Email info@stoketherapeutics.com
Diversity Spotlight 
Hispanic / Latine Founded
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
Stoke Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

TANGO Platform
A proprietary antisense oligonucleotide platform designed to increase protein expression from healthy genes by targeting RNA splicing.
Zorevunersen (STK-001)
An antisense oligonucleotide drug candidate developed using the TANGO platform for treating Dravet syndrome by increasing protein expression.

Research & Development

Stoke Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Stoke Therapeutics Logo
Post-IPO Equity - Stoke Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Stoke Therapeutics Logo
Post-IPO Equity - Stoke Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Stoke Therapeutics Logo
Post-IPO Equity - Stoke Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Stoke Therapeutics Logo
Post-IPO Equity - Stoke Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Stoke Therapeutics Logo
Post-IPO Equity - Stoke Therapeutics
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Stoke Therapeutics Logo
Post-IPO Equity - Stoke Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Stoke Therapeutics Logo
Post-IPO Equity - Stoke Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Stoke Therapeutics Logo
Post-IPO Equity - Stoke Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Stoke Therapeutics Logo
Post-IPO Equity - Stoke Therapeutics
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Stoke Therapeutics Logo
Post-IPO Equity - Stoke Therapeutics
—
obfuscation
— Post-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 12 Board Members and Advisors 5 Contacts 125

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 29, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 28, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

8,298
91.24%
 in past month

IT Spend

$4.3MThis year, Stoke Therapeutics is projected to spend $4.3M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Employment Projections Logo
Employment Projections
92
Amazon Web Services (AWS) Logo
Amazon Web Services (AWS)
91
Generation Z Recruiting Logo
Generation Z Recruiting
89

Actively Used Products

21Stoke Therapeutics uses 21 technology products and services including HTML5, Office 365, and  Wordpress, according to G2 Stack.

Active Website Tech Count

13Stoke Therapeutics is actively using 13 technologies for its website, according to BuiltWith. These include Common Crawl, HSTS, and  Amazon.

Total IP

42The intellectual property of Stoke Therapeutics includes 39 registered patents primarily in the 'Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering' category, according to IPqwery. Additionally, Stoke Therapeutics has registered 3 trademarks with the most popular class being 'Scientific and technological services', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Stoke Therapeutics's headquarters? Stoke Therapeutics is located in Bedford, Massachusetts, United States.Who invested in Stoke Therapeutics? Stoke Therapeutics has 9 investors including Alexandria Venture Investments and  RA Capital Management.When was the last funding round for Stoke Therapeutics? Stoke Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Stoke Therapeutics's competitors? Alternatives and possible competitors to Stoke Therapeutics may include LEXEO Therapeutics, Korro Bio, and  Amylyx Pharmaceuticals.How much funding has Stoke Therapeutics raised to date? Stoke Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|